Kirkland & Ellis and Wachtell, Lipton, Rosen & Katz are advising on the proposed $74 billion acquisition by pharmaceutical giant Bristol-Myers Squibb of New Jersey-based biotechnology firm Celgene Corp.
The deal, which would unite the resources of two of the world’s pioneers in the treatment of cancer, cardiovascular disease and other maladies, is expected to close in the third quarter of 2019, subject to antitrust and regulatory approval.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]